Back Hepatitis C

Hepatitis C

Achillion HCV NS5A Inhibitor + Sofosbuvir Shows High Early Cure Rate

An interferon-free dual combination of Achillion's hepatitis C virus NS5A inhibitor ACH-3012 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 8 weeks led to sustained virological response at 4 weeks post-treatment for people with HCV genotype 1 in a Phase 2 study, according to a company announcement.

alt

Vertex to Discontinue Sale of Telaprevir (Incivek) for Hepatitis C

Vertex Pharmaceuticals announced last week that it will stop selling its HCV protease inhibitor telaprevir (Incivek or Incivo) as of October 16, 2014. While the first generation direct-acting antivirals are more effective than pegylated interferon plus ribavirin alone, they are no match for newer drugs such as Gilead Sciences' sofosbuvir (Sovaldi) or AbbVie's forthcoming "3D" regimen in terms of efficacy or tolerability.

alt

July 28 Is World Hepatitis Day [VIDEO]

July 28 is World Hepatitis Day, an opportunity to raise awareness about viral hepatitis and its consequences. This year's theme -- "Think Again" -- emphasizes that while hepatitis B and C are major causes of death worldwide, viral hepatitis remains remarkably neglected. The World Health Organization (WHO) and others held a press briefing at the 20th International AIDS Conference last week in Melbourne to raise awareness.

alt

Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment

An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.

alt

AIDS 2014: AbbVie Hepatitis C Treatment Works Well for People on Methadone or Buprenorphine

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20thInternational AIDS Conference in Melbourne.

alt

New Hepatitis C Guidelines: Who Should Be Treated and When?

Everyone with chronic hepatitis C could potentially benefit from treatment with new direct-acting antivirals, but when resources are limited, people with advanced liver disease, those at greatest risk for complications, and those most likely to transmit HCV should be treated most urgently, according to new guidelines released this week from AASLD, IDSA, and IAS-USA.

alt

Interferon-free Daclatasvir + Asunaprevir Approved in Japan for Hepatitis C

Bristol-Myers Squibb's all-oral dual regimen of daclatasvir (Daklinza) plus asunaprevir (Sunvepra) has been approved for the treatment of chronic hepatitis C in Japan, where most people are infected with HCV genotype 1b, the company announced this week.

alt

New Treatments Could Dramatically Reduce Hepatitis C Burden

Widespread screening and use of new direct-acting antivirals could make hepatitis C a rare disease within the next 2 decades, according to results from a mathematical modeling study published in the August 5 edition of Annals of Internal Medicine. Universal screening and treatment could prevent more than 161,000 liver-related deaths, they projected.

alt

Survey Finds Most Primary Care Providers Unaware of New Hepatitis C Drugs

Nearly 75% of primary care physicians are unfamiliar with the most recently approved direct-acting antiviral drugs for hepatitis C, and about two-thirds are unaware of even the first-generation antivirals available since 2011, according to a recent survey by Decision Resources Group.

alt